AEON Biopharma, Inc. financial data

Symbol
AEON on NYSE
Industry
Pharmaceutical Preparations
Location
5 Park Plaza, Suite 1750, Irvine, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Priveterra Acquisition Corp. (to 7/24/2023)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 30.1 % +21.1%
Debt-to-equity -109 % -93.3%
Return On Equity 161 %
Return On Assets -2.17K % -108229%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 40M shares +7.57%
Common Stock, Shares, Outstanding 39.6M shares +6.53%
Entity Public Float 14.2M USD
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 39.5M shares +6.34%
Weighted Average Number of Shares Outstanding, Diluted 39.5M shares +6.34%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 972K USD -84.8%
Operating Income (Loss) -4.02M USD +98.6%
Nonoperating Income (Expense) -2.16M USD +84.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -6.17M USD +97.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -6.17M USD +97.9%
Earnings Per Share, Basic -0.16 USD/shares +98%
Earnings Per Share, Diluted -0.16 USD/shares +98%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 537K USD -96.7%
Assets, Current 2.37M USD -86%
Property, Plant and Equipment, Net 258K USD -27.5%
Operating Lease, Right-of-Use Asset 1.35M USD +317%
Other Assets, Noncurrent 29K USD 0%
Assets 4M USD -77.3%
Accounts Payable, Current 4.63M USD +15.4%
Employee-related Liabilities, Current 1.56M USD +53.2%
Liabilities, Current 10.7M USD -24.3%
Operating Lease, Liability, Noncurrent 1.2M USD +2215%
Liabilities 36.1M USD -75.3%
Retained Earnings (Accumulated Deficit) -434M USD +3.06%
Stockholders' Equity Attributable to Parent -153M USD +46.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -32.1M USD +75%
Liabilities and Equity 4M USD -77.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.6M USD +22.2%
Net Cash Provided by (Used in) Financing Activities 5M USD -16.7%
Net Cash Provided by (Used in) Investing Activities 260M USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 39.6M shares +6.53%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.6M USD +28.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 537K USD
Deferred Tax Assets, Valuation Allowance 54M USD +17.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 54.1M USD +17.3%
Operating Lease, Liability 1.33M USD +283%
Lessee, Operating Lease, Liability, to be Paid 1.51M USD +307%
Property, Plant and Equipment, Gross 502K USD 0%
Operating Lease, Liability, Current 128K USD -56.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 297K USD +1.71%
Lessee, Operating Lease, Liability, to be Paid, Year One 175K USD +124%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 173K USD +686%
Lessee, Operating Lease, Liability, to be Paid, Year Three 307K USD
Deferred Tax Assets, Operating Loss Carryforwards 28.6M USD +42.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 14.7M USD +32.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 318K USD
Operating Lease, Payments 80K USD +56.9%
Additional Paid in Capital 32K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 25K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 153K USD -32.6%
Share-based Payment Arrangement, Expense 1.6M USD -27.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%